Pending Class Action Lawsuit Against Hims & Hers Health, Inc. Over Securities Fraud Allegations

Lawsuit Filed Against Hims & Hers Health, Inc.



On July 7, 2025, Wolf Haldenstein Adler Freeman & Herz LLP made a significant announcement regarding a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS). This legal action is designed to protect the interests of investors who acquired securities from the company during a specific period, which spanned from April 29, 2025, to June 23, 2025. The lawsuit raises critical allegations that could have severe ramifications for the telehealth company and its shareholders.

Background of the Allegations



Hims & Hers Health, a well-known telehealth company offering prescription medications and personal care products, is embroiled in serious allegations of deception. According to the complaint, after announcing a promising collaboration with Novo Nordisk A/S on April 29, 2025, Hims & Hers faced backlash for allegedly promoting and selling counterfeit versions of the FDA-approved medication Wegovy®. These practices allegedly jeopardized patient safety and misled investors about the company's credibility and operational practices.

Claims of Deceptive Practices



During the class period, the lawsuit contends that executives made misleading statements about the safety and legitimacy of the products being offered. More specifically, it claims that Hims & Hers was engaged in the deceptive promotion of illegitimate versions of Wegovy®, raising concerns of patient safety. These actions purportedly created an atmosphere where investors were not fully informed about the risks associated with Hims & Hers’ operations.

On June 23, 2025, a press release from Novo Nordisk confirmed the termination of their partnership with Hims & Hers due to these serious allegations. This announcement resulted in a drastic decline in Hims & Hers' stock value—dropping by $18.26 per share, which represented a shocking 34% decrease, closing at $45.00. This financial blow indicates the potential severity of the situation both for the company and its investors.

Importance of Contacting Legal Representation



The lead plaintiff motion deadline for this class action lawsuit has been set for August 25, 2025. Therefore, it is crucial for investors who believe they have been wronged to act promptly. Wolf Haldenstein is encouraging those affected to reach out before the deadline. The firm possesses over 125 years of legal experience and specializes in securities litigation, making them a trusted ally for investors navigating this complicated legal terrain.

How to Join the Lawsuit



Investors who acquired shares of Hims & Hers during the class period and wish to explore their legal rights are urged to contact Wolf Haldenstein. An informative process will be provided for those interested in joining the lawsuit, ensuring that their concerns and claims are heard in court.

For investors seeking assistance, Wolf Haldenstein can be reached by phone at (800) 575-0735, or via email. More information about the firm and the lawsuit can also be found on the official website.

Conclusion



As the class action lawsuit progresses, the investors' rights and interests will be at the forefront of legal discussions. This situation underlines the critical importance of transparency in corporate practices and the need for investors to remain vigilant against misleading claims and practices within the marketplace.

Investors are encouraged to stay informed and consider seeking representation to navigate this unfolding situation and protect their investments effectively.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.